Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.30 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.30 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7431168 | 0.91 | ACHE (0.38) | ACHEADRA2CCFDSMYD3ROCK2 | |
| Trifluoroacetic Acid SCHEMBL5213057 | 0.89 | ACHE (0.34) | ACHEHDAC11HDAC8HDAC6HTR2C | |
| Trifluoroacetic Acid SCHEMBL5212873 | 0.89 | ACHE (0.34) | ACHEHDAC11HDAC8HDAC6HTR2C | |
| Trifluoroacetic Acid SCHEMBL5210906 | 0.89 | ACHE (0.39) | ACHEHDAC11HDAC8HDAC6ADRA2C | |
| Trifluoroacetic Acid SCHEMBL7431702 | 0.88 | NAMPT (0.34) | ACHEHDAC11HDAC8HDAC6HTR2C | |
| Trifluoroacetic Acid SCHEMBL7424902 | 0.87 | ACHE (0.34) | ACHEHDAC11HDAC8HDAC6 | |
| Trifluoroacetic Acid SCHEMBL7422801 | 0.87 | ACHE (0.35) | ACHEHTR2CADRA2CCFD | |
| Trifluoroacetic Acid SCHEMBL7428691 | 0.85 | CFD (0.43) | ACHEHDAC8HDAC6HTR2CCFD | |
| Trifluoroacetic Acid SCHEMBL7423644 | 0.84 | ACHE (0.39) | ACHEADRA2C | |
| Trifluoroacetic Acid SCHEMBL5216054 | 0.84 | ACHE (0.38) | ACHEADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240154-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| EP-1240154-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001044226-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | ACHE 480/4885HDAC11 2018/4885HDAC8 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.